Sertraline - Therapeutic use
Research News and Information

Saturday, November 21, 2009

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.

19 Oct 2009 CONTEXT: Studies of depressed psychiatric patients have shown that antidepressant efficacy can be increased by augmentation with omega-3 fatty acids. OBJECTIVE: To determine whether omega-3 improves the response to sertraline in patients with major ... Read more...

Antidepressant medication use during breastfeeding.

30 Aug 2009 We performed an electronic search by using MEDLINE, PreMEDLINE, Current Contents, Biological Abstracts, and PsycINFO from June 2002 to December 2008 using the following terms: "antidepressant drugs", "antidepressive agents", "human milk", ... Read more...

Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants.

30 Aug 2009 CONTEXT: Major depressive disorder (MDD) after acute coronary syndrome (ACS) is associated with an increased mortality rate. We observed the participants of the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) to establish features ... Read more...

Latest indexed articles for 'Sertraline - Therapeutic use'

These are the very latest articles for this heading:

• Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. 19 Oct 2009
• Antidepressant medication use during breastfeeding. 30 Aug 2009
• Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. 30 Aug 2009
• Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. 30 Jul 2009
• A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). 30 Jul 2009
• Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. 27 Jul 2009
• Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 30 Jun 2009
• Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. 29 Jun 2009
• Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. 29 Jun 2009
• [Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness] 29 Jun 2009
• Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. 28 Jun 2009
• Persistence and compliance to antidepressant treatment in patients with depression: a chart review. 14 Jun 2009
• What you believe is what you want: modeling PTSD-related treatment preferences for sertraline or prolonged exposure. 10 Jun 2009
• Behavioral therapy, sertraline, or both in childhood anxiety. 2 Jun 2009
• Behavioral therapy, sertraline, or both in childhood anxiety. 2 Jun 2009
• Behavioral therapy, sertraline, or both in childhood anxiety. 2 Jun 2009
• Behavioral therapy, sertraline, or both in childhood anxiety. 2 Jun 2009
• Use of SSRIs in pregnancy: neonatal implications. 30 May 2009
• Putative neuroleptic malignant syndrome associated with sertraline withdrawal. 30 May 2009
• Depression and cognitive complaints following mild traumatic brain injury. 30 May 2009

See a longer list of these articles.

Technical information about 'Sertraline'

Definition: A selective serotonin uptake inhibitor that is used in the treatment of depression.

Chemical name: 1-Naphthalenamine,1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-

Registry Number: 79617-96-2

Descriptor UI: D020280

Alternative terms: Sertraline; Zoloft; Altruline; Parke Davis Brand of Sertraline Hydrochloride; Lustral; Pfizer Brand of Sertraline Hydrochloride; Roerig Brand of Sertraline Hydrochloride; Apo-Sertraline; Apo Sertraline; Apotex Brand of Sertraline Hydrochloride; Aremis; Esteve Brand of Sertraline Hydrochloride; Besitran; Sealdin; Lacer Brand of Sertraline Hydrochloride; Gladem; Boehringer Ingelheim Brand of Sertraline Hydrochloride; Novo-Sertraline; Novo Sertraline; Novopharm Brand of Sertraline Hydrochloride; ratio-Sertraline; ratio Sertraline; Ratiopharm Brand of Sertraline Hydrochloride; Rhoxal-sertraline; Rhoxal sertraline; Rhoxalpharma Brand of Sertraline Hydrochloride; Sertraline Hydrochloride; Hydrochloride, Sertraline; Sertraline Hydrochloride (1S-cis)-Isomer; Gen-Sertraline; Gen Sertraline; Genpharm Brand of Sertraline Hydrochloride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antidepressive Agents; Serotonin Uptake Inhibitors;

Tree Number: D02.092.705.800; D02.455.426.559.847.638.845.800; D04.615.638.845.800;

History Note: 99; use SERTRALINE (NM) 1983-98